Pharma pipeline intelligence

Clinical Pharma Intel

Monitor ClinicalTrials.gov, EudraCT and CTIS for phase transitions, enrolment updates, primary endpoint readouts and FDA/EMA regulatory decisions. Real-time alerts on catalyst events.

Scientific Literature Search

Semantic search across PubMed, bioRxiv, medRxiv and EMBASE. Cluster papers by mechanism of action, indication, patient population and competing compound. Ranked by recency and citation velocity.

Patent Landscape

Map composition-of-matter, formulation and method-of-treatment patents for any target or compound. Identify expiry cliffs, paragraph IV challenges and freedom-to-operate risks across jurisdictions.

Competitive Deep Dive

Cross-reference pipeline assets with competitor investor presentations, regulatory filings, partnership announcements and hiring patterns. Know the competitive landscape before Phase III readout.

Track every pipeline asset across clinical stage, mechanism and indication. Get catalyst calendars and endpoint readout risk scores in one structured query.

Identify licensing and acquisition targets before they reach Phase III premium. Patent expiry analysis + competitive gap mapping to justify term sheet valuations.

Clinical phase transition alerts, FDA PDUFA date tracking and sentiment shift from literature velocity. Enter and exit positions on data, not rumour.

“We had clinical_pharma_intel running on 140 trials across 6 indications. The Phase III readout alert on a competitor's NASH programme arrived 4 hours before it hit the wire. That alpha was real.”

“The patent landscape on our lead oncology candidate identified a formulation patent we had missed entirely. We filed a design-around six months before our IND submission.”

“Scientific literature search gave us a publication velocity signal on a target that told us a competitor was doubling down. We accelerated our term sheet timeline by three months.”